NAV

AG-858

Identification

Generic Name
AG-858
DrugBank Accession Number
DB05502
Background

AG-858 (autologous heat-shock protein 70 peptide vaccine) is a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in leukemia (myeloid).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

AG-858 is an investigational personalized vaccine designed to treat cancer while minimizing the side effects that are often associated with other treatment options. Patients undergo a blood-filtering process called leukapheresis, during which white blood cells are collected. The white blood cells are sent to Antigenics so that the personalized vaccines can be made. Vaccines provoke the body’s natural disease-fighting response. A vaccine that is made from the patient’s own cancerous cells is designed to contain the particular cancer’s ‘fingerprint.’ Injection of the AG-858 vaccine may cause the body to attack any cells bearing this cancer fingerprint.

Mechanism of action

Under normal conditions, heat shock proteins are not found outside the cell. But if a cancerous or infected cell has become so sick that it dies and its membrane bursts, all of the cell’s contents spill out, including heat shock proteins that are bound to peptides. These extracellular HSPs send a very strong ‘dange r signal’ to the immune system, instructing it to destroy the other diseased cells. This is how it works:

* A sick cell dies and ruptures, spilling out the HSP-peptide complexes.
* These extracellular complexes of HSPs and peptides are detected by circulating immune system cells called antigen-presenting cells (APCs). These APCs include cells called macrophages and dendritic cells.
* The HSP complexes bind the CD91 receptor on the APC cell surface. The APC can then take in the HSP complexes.
* Once the APCs have taken in the HSP complexes, they travel to the lymph nodes, which are clusters of immune system tissue that are distributed throughout the body.
* In the lymph nodes, the APCs take the peptides that were associated with the HSPs and re-present them on the APC cell surface. These peptides are antigenic — meaning that they can stimulate an immune response.
* In the lymph nodes, specialized immune cells called T cells ‘see’ these peptides and are then programmed to seek out cells bearing these specific, abnormal peptides.
* Because every person and every cancer is different, the unique repertoire of antigenic peptides represents that individual patient’s specific cancer’s ‘fingerprint.’ The T cells are activated to target and destroy cancer cells bearing this fingerprint.
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Well-tolerated — it’s designed to leave your healthy cells alone so the side effects of most conventional cancer treatments are minimized

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910176

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentChronic Myeloid Leukemia (CML)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52